SynthesisDie Anaesthesiologie2024
Effect of remimazolam for general anesthesia on postoperative nausea and vomiting : A systematic review and meta-analysis.
Synthesis in Die Anaesthesiologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative clinical outcomes of remimazolam in regional anesthesia: a systematic review of sedation and safety parameters.BMC anesthesiology · 2026Pooled it
- Effects of Ciprofol- versus Remimazolam-Based Total Intravenous Anesthesia on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial.BMC anesthesiology · 2025Trial
- Remimazolam Versus Propofol for General Anesthesia in Older Adults Undergoing Colon Cancer Surgery: A Systematic Review and Meta-Analysis of Comparative Studies.Pharmaceutics · 2026Review
- ED50 and ED95 of Remimazolam Combined with Sufentanil for Sedation During Ultrasound-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Prospective Dose-Finding Study.Drug design, development and therapy · 2026Article
- The Influence of Remimazolam versus Propofol on Quality of Emergence and Sleep in Elderly Patients After Spinal Surgery: A Non-Randomized Observational Study.Drug design, development and therapy · 2026Observational
- Comparative Effects of Remimazolam and Propofol on Intraoperative Hypertension and Hypotension During Robot-Assisted Laparoscopic Gynecologic Surgery: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Adverse Events Following Vitreoretinal Surgeries Under Adequacy of Anesthesia with Combined Paracetamol/Metamizole-Additional Report.Journal of clinical medicine · 2025Article
- Article
- Achieving relief from nausea and vomiting: from intraoperative to postoperative management.Korean journal of anesthesiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenzodiazepines reduce postoperative nausea and vomiting (PONV); however, conflicting results have been reported regarding the use of remimazolam, a novel benzodiazepine.
objectiveThis meta-analysis examines whether remimazolam reduces PONV incidence compared with propofol or volatile agents used in general anesthesia. MATERIAL AND
methodsElectronic databases, including PubMed, EMBASE, CENTRAL, and Web of Science, were searched on 31 July 2023. The primary outcome was the incidence of PONV. Secondary outcomes included PONV severity, rescue antiemetic use, amounts of remifentanil used, and participant satisfaction scores. Odds ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. The risk of bias (RoB) was assessed using the Cochrane RoB2 tool.
resultsA total of 1514 adult patients from 11 randomized controlled trials were included. The incidences of PONV in the remimazolam and control groups were 16.1% and 16.5%, respectively. Remimazolam did not increase the incidence of PONV (OR 0.62; 95% CI, 0.37-1.04; p = 0.0676; I
conclusionRemimazolam did not increase PONV risk compared to propofol and reduced PONV incidence compared to volatile agents, with higher participant satisfaction. To validate the present findings, further well-planned large clinical trials are required.
Indexed as
Identifiers
39271579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.